The use of {99m}Tc-Al[2]O[3] for detection of sentinel lymph nodes in cervical cancer patients by Sinilkin, Ivan Gennadjevich et al.
The use of 99mTc-Al2O3 for detection of sentinel lymph nodes 
in cervical cancer patients 
I G Sinilkin
1, 2
, V I Chernov
1, 2
, A Yu Lyapunov
1
, A A Medvedeva
1, 2
,  
R V Zelchan
1, 2
, A L Chernyshova
1
, L A Kolomiets
1, 3
 
1Tomsk Cancer Research Institute, Russia, Tomsk, Kooperativny street, 5 
2Tomsk Polytechnic University, Russia, Tomsk, Lenina street, 30 
3Siberian State Medical University, Russia, Tomsk, Moskovsky Trakt, 2 
 
E-mail: Lyapunov1720.90@mail.ru 
Abstract: The purpose of the study was to evaluate the feasibility of using 99mTc-Al2O3-
based radiopharmaceutical, a novel molecular imaging agent for sentinel lymph node detection 
in patients with invasive cervical cancer. The study included 23 cervical cancer patients 
(T1aNхMх- T2bNхMх) treated at the Tomsk Cancer Research Institute.  At 18 hours before 
surgery, 80 MBq of the 99mTc-Al2O3 were injected peritumorally, followed by single-photon 
emission computed tomography (SPECT) of the pelvis and intraoperative SLN identification. 
Twenty-seven SLNs were detected by SPECT, and 34 SLNs were identified by intraoperative 
gamma probe. The total number of identified SLNs per patient ranged from 1 to 3(the mean 
number of SLNs was 1.4 per patient). The most common site for SLN detection was the 
external iliac region (57.2%), followed by the internal iliac, obturator, presacral and retrosacral 
regions (they amounted to 14%, respectively),and the parametrial region (1%). Sensitivity in 
detecting SLNs was 100% for intraoperative SLN identification and 79% for SPECT image.   
1. Introduction 
Cervical cancer is estimated to be the 2-nd most common cancer in women worldwide, accounting for 
7% of malignancies in women. Approximately 15, 000 new cases of invasive cervical cancer are 
diagnosed annually in Russia. The peak age at diagnosis of invasive cervical cancer is between 15 and 
54 years [1].  
The objective assessment of pelvic lymph nodes is an integral component of definitive surgical 
management for cervical cancer. Regional lymph node status reflects the metastatic potential of the 
tumor.  Currently available non-invasive imaging methods such as ultrasound, computed tomography, 
magnetic resonance imaging and nuclear scintigraphy are unable to provide information about the 
presence or absence of lymph node metastases. Micrometastases can only be diagnosed by 
microscopically, using morphological or molecular biology techniques. Visualization and assessment 
of lymph nodes during surgical removal of the tumor in order to detect lymph node metastasis is of 
great importance [7]. 
Sentinel lymph node biopsy is becoming increasingly recognized as a standard technique for 
determining the status of lymphatic spread. The term “sentinel lymph node” was used for the first time 
by E.A. Gould in 1960 and supplemented then by R.M. Cabanas in 1977 [12, 13]. The concept of 
sentinel lymph node (SLN) is based on the theory of an orderly progression of tumor cells within the 
lymphatic system in the initial phase of the metastatic process, assuming that early lymphatic 
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metastases are found first within the first-line tumor draining lymph node, the sentinel lymph node 
[13]. If the SLN is free of metastatic disease, all other lymph nodes will also be free of disease. 
Identification of SLNs may help some patients avoid more extensive lymph node surgery, thus 
minimizing postoperative morbidity and significantly improving life quality of the patients.   
Clinically, radioactive nanocolloids have been used for investigations of lymphatic drainage, and 
recently, more specifically for identification of the sentinel node in investigations of metastatic spread 
of some cancers [3, 9,14]. 
The use of radiopharmaceuticals for SLN detection such as Nanocoll, 99mTc-nanocolloid, 
Nanocis, Microlite and Sulfurcolloid have several drawbacks [10, 11]. Their applications are limited 
by their complex manufacturing process and high cost. Furthermore, the extremely low accumulation 
of these radiopharmaceuticals in SLNs may lead to further redistribution of a radiotracer through the 
lymphatic collector and an erroneous interpretation of the results [5, 9].  
In this regard, there was a need to develop a novel lymphotropic radiopharmaceutical, which would 
be devoid of these drawbacks. 
The basic precondition for using the nanoscale Al2O3 gamma-alumina as a "carrier" of  99mTc 
label is its lower toxicity compared with antimony and rhenium compounds in combination with good 
absorption properties, availability, and low cost. 
A specific feature of this compound is an organic coating of nanoparticles [8]. During passage 
through the lymphatic system, nanoparticles lose their organic coating and persistent uptake in SLN 
without redistribution in the body. In addition, 99mTc-Al2O3 has an optimum nanoparticle size from 
50 to 100 nm, whereby the tracer quickly leaves the injection site and migrates through the lymphatic 
system [3, 9, 14]. 
The purpose of the study was to evaluate the feasibility of using the new radiopharmaceutical, 
based on technetium-99m-labeled gamma-alumina (99mTc-Al2O3), for the detection of sentinel lymph 
nodes in cervical cancer patients.  
 
2. Materials and methods 
Between 2015 and 2016, 23 patients with cervical cancer (T1aNхMх- T2bNхMх) were treated at the 
Gynecological Oncology Department of the Tomsk Cancer Research Institute. Non-keratinizing 
squamous cell carcinoma was histologically verified in all patients.  
The day before surgery, four submucosal injections of 99mTc-Al2O3 at a dose of 20 MBq per 
quadrant were made in each quadrant around the cervical tumor. Patients were submitted to single 
photon emission computed tomography (SPECT) of the pelvis 18 hours after the injection of the 
radioactive isotope.  Images were obtained  using a double-headed gamma-camera (E.CAM 180, 
Siemens). 
A total of 16 projection images were recorded into a 64х64 matrix (30 seconds per projection). The 
scan images were analyzed using the manufacturer software (e.soft, Siemens, Germany). Three-
dimensional images of the abdomen, sagittal, transverse and coronal sections were obtained (fig.1). 
Single photon emission computed tomography scans were visually assessed. 
For intraoperative detection of sentinel lymph nodes, the hand-held gamma-probe Gamma Finder 
II® was used, which allowed the surgeon to precisely locate gamma radiation source and obtain 
accurate information about the distribution of the radionuclide in tissues and organs of the patient. The 
intraoperative gamma probe-guidedof SLNs was performed by the surgeon after the opening of the 
retroperitoneal space (fig.2).The registered gamma radiation level was displayed in numerical values. 
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(а) Visualization of sentinel lymph 
nodes in the projection of external 
iliac lymph nodes on the right and 
left. 
 (b) Sentinel lymph nodes in the 
projection of the internal iliac lymph 
nodes on the left and the right and 
the right external iliac lymph nodes. 
Figure 1. Sentinel lymph. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The lymph node with radioactivity of at least three times more than the background counts was 
defined as a sentinel lymph node. The sentinel lymph node was marked and separately sent for express 
cytological examination. The lymph node was sectioned transversely into 2mm slices. Depending on 
the size of the node, 6–10 imprints were made from each slice by gently touching the cut surface of the 
node onto a glass slide. Cytological specimens were stained for 15 seconds using the kit for rapid 
staining of blood smears (Leucodiff 200) and examined with a Zeiss Axio Scope.  
Patients were then underwent iliac-pelvic lymph node dissection. After lymphodissection, the removed 
lymph nodes were re-examined with gamma probe to detect SLNs missed during intraoperative 
examination(fig.3). 
The true number of SLNs was calculated as the sum of SLNs identified removed lymph nodes. 
Statistical analysis was performed using the IBM SPSS statistics 20.0 package. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Intraoperative gamma probe-guided SLN identificationin the area of 
the iliac-pelvic lymphadenectomy using Gamma Finder II® probe. 
Sentinel lymph 
nodes 
Injection site 
Sentinel 
lymph nodes 
PowerPlants2016 IOP Publishing
IOP Conf. Series: Materials Science and Engineering 135 (2016) 012043 doi:10.1088/1757-899X/135/1/012043
3
  
 
Figure 3. Direct radiometry macropreparations. 
 
3. Results and discussion 
The use of 99mTc-Al2O3 enabled SLNs to be identified by SPECT and intraoperative gamma probe 
procedure in all 23 patients. A total of 27 SLNs were identified by means of single photon emission 
computed tomography (SPECT). The proportion of radiation taken up by the SLN was 7% of the total 
administered dose, thereby indicating high accumulation of the radiopharmaceutical in SLNs. The 
intraoperative SLN assessment followed by the measurement of radioactivity in surgical specimen 
enabled identification of 34 SLNs. The radioactive count at the tumor injection site ranged from 1500 
to 2000 cps (counts per second), whereas it ranged from 80 to 200 cps in sentinel lymph nodes.  The 
percentage of tracer uptake was 24% of the total administered dose. High radioactivity counts were 
registered only in SLNs, the non-SLNs had a background count (0-3cps), indicating that there was no 
redistribution of the radiopharmaceutical.  
The most common site for SLN detection was the external iliac region (57.1%), followed by the 
internal iliac, obturator, presacral and retrosacral regions (they amounted to 14%, respectively), and 
the parametrial region (1%). The excised SLNs were evaluated by imprint cytology with subsequent 
routine histological examination. All lymph nodes including SLNs and non-SLNs were metastasis-
negative, thereby indicating that there was no phenomenon of “jumping” nodal metastases.  
The intraoperative gamma probe procedure demonstrated 100% sensitivity for SLN detection, 
compared to SPECT image with sensitivity of 79%. 
Various techniques of SLN identification are widely discussed in the published literature. 
Currently, most investigators propose that the blue dye and isotope complement each other, and the 
detection of SLN is more successful using combined dye- isotope technique, with sensitivity and 
specificity approaching 100%. In our study, the use of 99mTc-Al2O3, a novel molecular imaging agent 
has shown promising results in detecting SLNs with high sensitivity. 
The frequency of lymph node metastasis in patients with stage I-II cervical cancer does not exceed 
15%, which confirms the relevance of the concept of "sentinel" lymph node. The routine, widespread 
use of 99mTc-Al2O3, specially developed for SLN identification, would greatly improve the quality of 
life of 80-90% of patients with early-stage cervical cancer. Sentinel lymph node biopsy may be a 
reasonable alternative to avoid extensive pelvic lymph nodes dissection in early stage cervical cancer 
patients with negative SLNs, thereby  significantly reducing the length of patients’ hospital stay and 
speeding up their rehabilitation. 
Conclusion 
The novel radiopharmaceutical based on 99mTc-Al2O3 has high accumulation in sentinel lymph nodes 
without the evidence of  further redistribution along the lymphatic collector, thus significantly 
facilitating scintigraphic and gamma probe-guided intraoperative SLN identification. 
Single photon emission computed tomography and intraoperativegamma probe-
guidedidentification performed after paratumoral injection of 99mTc-Al2O3 enable the detection of 
SLNs with 79 and 100% sensitivity, correspondently. 
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